Lipella Pharmaceuticals Inc.
LIPO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | -0.00 | -0.09 |
| FCF Yield | -86,381.61% | -38.35% | -54,205.86% | -30.98% |
| EV / EBITDA | 1.25 | -32.55 | 0.00 | -0.74 |
| Quality | ||||
| ROIC | -72.75% | -2.95% | -32,172.45% | -73.78% |
| Gross Margin | 0.00% | -0.91% | 100.00% | -511.71% |
| Cash Conversion Ratio | 0.61 | 1.08 | 1.09 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -21.70% | -0.47% | 37.26% | 42.81% |
| Free Cash Flow Growth | -164,417.43% | 99.90% | -143,893.06% | -51.65% |
| Safety | ||||
| Net Debt / EBITDA | 1.25 | -29.79 | 0.00 | 1.48 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -69.10 | 0.06 | 11.01 |